Skip to main content
Equibles

AZN · Astrazeneca PLC · Webcasts, Transcripts & Audio

Track AZN — free

Use AZN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AZN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$156.90 -0.80 (-0.51%) At close · Oct 2
Rebalance outlook locked
Market Cap
$254.67B
Shares
1.55B
Volume · Oct 2 3.44M Avg daily vol (3M) 3.4M

Astrazeneca PLC Webcasts

Earnings calls, investor updates, investor days and conferences for Astrazeneca PLC (AZN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲13.3% $12.94B $1.93B '24 Q2 24-06-30 ▲11.7% $14.46B $2.45B '25 Q2 25-06-30 LATEST ▲6.4% $15.38B $2.51B '26 Q2 26-07-27
Earnings call
FY26 · Q2
2026-07-27
Astrazeneca PLC (AZN) Q2 2026 Earnings Call
Revenue
$15.38B
▲ 6.4% YoY
Diluted EPS
$1.61
▲ 2.5% YoY
Gross margin
83.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Astrazeneca PLC (AZN) Q1 2026 Earnings Call Transcript
Confident tone Q1 financial performance Upcoming launches Pipeline and R&D
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-10
Astrazeneca PLC (AZN) Q4 2025 Earnings Call Transcript
Confident tone Pipeline and Phase III catalysts Revenue and financial growth Geographic diversification
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Astrazeneca PLC (AZN) Q3 2025 Earnings Call Transcript
Confident tone Rare Disease and Biopharmaceuticals Financial performance and guidance Pipeline and Phase III readouts
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Astrazeneca PLC (AZN) Q2 2025 Earnings Call Transcript
Confident tone Oncology portfolio expansion Rare disease and C5 franchise China VBP and Farxiga
Revenue
$14.46B
▲ 11.7% YoY
Diluted EPS
$1.57
▼ 36.7% YoY
Gross margin
82.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Astrazeneca PLC (AZN) Q1 2025 Earnings Call Transcript
Confident tone Oncology Performance (Tagrisso, Calquence, Imfinzi) Tariffs and Manufacturing Footprint China and Emerging Markets
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Astrazeneca PLC (AZN) Q4 2024 Earnings Call Transcript
Confident tone 2024 financial performance Gross margin guidance China business and investigations
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Astrazeneca PLC (AZN) Q3 2024 Earnings Call Transcript
Confident tone Broad-based revenue growth across regions U.S. manufacturing and R&D investment China investigations and business impact
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Astrazeneca PLC (AZN) Q2 2024 Earnings Call Transcript
Confident tone Revenue and Earnings Growth China and Emerging Markets Inflation Reduction Act / IRA
Revenue
$12.94B
▲ 13.3% YoY
Diluted EPS
$2.48
▲ 6% YoY
Gross margin
83.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Astrazeneca PLC (AZN) Q1 2024 Earnings Call Transcript
Confident tone Biopharmaceuticals and respiratory Organizational structure Capital allocation and M&A
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Astrazeneca PLC (AZN) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–11 of 11 webcasts
Key facts CIK 901832 CUSIP G0593M107 13F (30d) 30 filings 26 filers Visit website Investor relations